FDA-approved, for example:

• Acute insomnia
• Chronic insomnia
• Insomnia characterized by middle of the night awakenings with difficulty falling back asleep

Note: The above list may not include all FDA-approved indications.

Please note: In the case where the prior authorization (PA) status column indicates PA, both the brand and generic (if available) require PA. Typically, the generic is preferred when available unless the brand-name drug appears on the MassHealth Brand Name Preferred Over Generic Drug List. In general, when requesting the non-preferred version, whether the brand or generic, the prescriber must provide medical records documenting an inadequate response or adverse reaction to the preferred version, in addition to satisfying the criteria for the drug itself.

• Documentation of the following is required:
  • All PA requests must include clinical diagnosis, drug name, dose, and frequency; and
  • Member’s current medications.
• A preferred drug may be designated for this therapeutic class. In general, MassHealth requires a trial of the preferred drug or clinical rationale for prescribing a non-preferred drug within a therapeutic class. Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at www.mass.gov/druglist.
• Additional criteria may apply depending upon diagnosis and/or requested medication (see below).

 

 

Belsomra

• Documentation of all of the following is required: 
  • an appropriate diagnosis; and
  • an inadequate response or adverse reaction to two of the following, or a contraindication to all of the following: eszopiclone, Rozerem, zaleplon, zolpidem immediate-release or extended-release; and
  • one of the following:
    • requested quantity is ≤ 30 units/month; or
    • medical necessity for > 30 units per month.

 

 Edluar

• Documentation of all of the following is required:
  • an appropriate diagnosis; and
  • clinical rationale for a sublingual formulation; and
  • one of the following:
    • requested quantity is ≤ 30 units/month; or
    • medical necessity for > 30 units per month.

 

eszopiclone, Rozerem, zaleplon, zolpidem 10 mg tablet, and zolpidem extended-release tablet (quantities > 30 units/month)

• Documentation of all of the following is required:
  • appropriate diagnosis; and
  • medical necessity for exceeding the quantity limit.

   

Silenor

• Documentation of all of the following is required:
  • an appropriate diagnosis; and
  • an inadequate response or adverse reaction to one of the following, or a contraindication to all of the following: doxepin capsule or liquid, eszopiclone, Rozerem, zaleplon, zolpidem immediate-release or extended-release; and
  • one of the following:
    • requested quantity is ≤ 30 units/month; or
    • medical necessity for > 30 units per month.

  

zolpidem 1.75 mg, 3.5 mg sublingual tablet

• Documentation of all of the following is required:
  • an appropriate diagnosis; and
  • one of the following:
    • clinical rationale for a sublingual formulation; or
    • an inadequate response or adverse reaction to three of the following: eszopiclone, zaleplon, zolpidem immediate-release, zolpidem extended-release; and
  • one of the following:
    • requested quantity is ≤ 30 units/month; or
    • medical necessity for > 30 units per month.

  

zolpidem 5 mg tablet (quantities > 45 units/month)

• Documentation of all of the following is required:
  • an appropriate diagnosis; and
  • medical necessity for exceeding the quantity limit.

  

Zolpimist

• Documentation of all of the following is required:
  • an appropriate diagnosis; and
  • requested dose and frequency does not exceed one canister/month; and
  • one of the following:
    • an inadequate response, adverse reaction, or contraindication to all of the following: Belsomra, doxepin capsule, liquid, or tablet, eszopiclone, Rozerem, zaleplon, zolpidem immediate-release or extended-release; or
    • both of the following:
      • clinical rationale for a non-tablet dosage form; and
      • medical necessity for use of the requested agent instead of zolpidem sublingual tablets.

 

Brand-name Ambien CR

• Documentation of all of the following is required:
  • an appropriate diagnosis; and 
  • an inadequate response (defined as ≥ 30 days of therapy) or adverse reaction to eszopiclone; and
  • medical records documenting an inadequate response or adverse reaction to generic zolpidem extended-release tablet; and
  • one of the following:
    • requested quantity is ≤ 30 units/month; or
    • medical necessity for > 30 units/month.

  

In addition to individual drug PA criteria where applicable, some behavioral health medications are subject to additional polypharmacy and age limit restrictions.

 

Behavioral Health Medication Polypharmacy (pharmacy claims for any combination of 4 or more behavioral health medications [i.e., alpha₂ agonists, antidepressants, antipsychotics, atomoxetine, benzodiazepines, buspirone, cerebral stimulants, hypnotic agents, and mood stabilizers] within a 45-day period) for members < 18 years old

• For all requests, individual drug PA criteria must be met first where applicable.
• For regimens including ≤ 2 mood stabilizers (also includes regimens that do not include a mood stabilizer), documentation of the following is required:
  • one of the following:
    • member had a recent psychiatric hospitalization (within the last three months); or
    • member has a history of severe risk of harm to self or others; or
  • all of the following:
    • appropriate diagnoses and
    • treatment plan including names of current behavioral health medications and corresponding diagnoses; and
    • prescriber is a specialist (e.g.,  psychiatrist, neurologist) or consult is provided.

 

• For regimens including ≥ 3 mood stabilizers, documentation of the following is required:
  • one of the following:
    • member had a recent psychiatric hospitalization (within the last three months); or
    • member has a history of severe risk of harm to self or others; or
  • all of the following:
    • appropriate diagnoses; and
    • treatment plan including names of current behavioral health medications and corresponding diagnoses; and
    • prescriber is a specialist (e.g., psychiatrist, neurologist) or consult is provided; and
    • one of the following:
      • member has a seizure diagnosis only; or
      • member has an appropriate psychiatric diagnosis and one of the following:
        • Cross-titration/taper of mood stabilizer therapy; or
        • Inadequate response or adverse reaction to two monotherapy trials and/or multiple combination therapy trials as clinically appropriate; or
      • member has a diagnosis in which mood stabilizers may be clinically appropriate (e.g., migraine, neuropathic pain)  and documentation that other clinically appropriate therapies have been tried and failed; therefore, multiple mood stabilizers are needed; or
      • member has  psychiatric and comorbid diagnosis in which mood stabilizers may be clinically appropriate  (e.g., migraine, neuropathic pain) and documentation that other clinically relevant therapies have been tried and failed; therefore, multiple mood stabilizers are needed, and one of the following:
        • Cross-titration/taper of mood stabilizer therapy; or
        • Inadequate response or adverse reaction to two monotherapy trials and/or multiple combination therapy trials as clinically appropriate.

SmartPA: Claims will usually process at the pharmacy without a PA request if the member is < 18 years of age, has a history of MassHealth medical claims for seizure, and has a history of paid MassHealth pharmacy claims for four or less behavioral health medications within the past 60 days and one mood stabilizer agent is identified as being used for seizure only.^†

 

eszopiclone, zaleplon, zolpidem tablet, and zolpidem extended-release tablet for members < six years old

• For all requests, individual drug PA criteria must be met first where applicable.
• Documentation of the following is required for members with a diagnosis of insomnia with other behavioral health comorbidities excluding ADHD:
  • treatment plan including name of current hypnotic agent and corresponding diagnosis; and
  • prescriber is a specialist (e.g., psychiatrist, neurologist) or consult is provided.

 

• Documentation of the following is required for members with a diagnosis of insomnia without behavioral health comorbidities:
  • treatment plan including name of current hypnotic agent and corresponding diagnosis; and
  • prescriber is a specialist (e.g., psychiatrist, neurologist) or consult is provided; and
  • inadequate response (defined by ≥ 10 days of therapy), adverse reaction, or contraindication to melatonin.

 

• Documentation of the following is required for members with a diagnosis of insomnia with comorbid ADHD:
  • treatment plan including name of current hypnotic agent and corresponding diagnosis; and
  • prescriber is a specialist (e.g., psychiatrist, neurologist) or consult is provided; and
  • inadequate response (defined by ≥ 10 days of therapy), adverse reaction, or contraindication to melatonin; and
  • inadequate response (defined by ≥ 10 days of therapy), adverse reaction, or contraindication to clonidine.

 

Other hypnotic agents (Belsomra, Edluar, Silenor, zolpidem 1.75 mg, 3.5 mg sublingual tablet, and Zolpimist) for members < six years old

• For all requests, individual drug PA criteria must be met first where applicable.
• Documentation of the following is required:
  • treatment plan including name of current hypnotic agent and corresponding diagnosis; and
  • prescriber is a specialist (e.g., psychiatrist, neurologist) or consult was provided.

 

†Note: The decision on whether PA is required is based upon information available in the MassHealth medical claim and pharmacy claim databases. The MassHealth database contains member information exclusive to MassHealth, and no other health plans.